Evotec (NASDAQ:EVO) announced today that its Seattle-based subsidiary, Just - Evotec Biologics, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to optimize the manufacturing of medical countermeasures against life-threatening filoviruses.
Operating under the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), the multi-year award is valued at up to $10 million if all options are exercised.
The project focuses on a monoclonal antibody (mAb) cocktail targeting both the Ebola virus (EBOV) and the Sudan virus (SUDV).
While treatments exist for the Zaire ebolavirus, there are currently no FDA-approved therapeutics for the Sudan virus, making this collaboration a critical pillar of national health security.
Just - Evotec Biologics will leverage its proprietary J.DESIGN platform to handle molecular optimization, highly productive cell line development, and process scale-up.
A primary objective of the partnership is to ensure that these life-saving treatments can be produced at high yields and rapidly deployed during emergency outbreaks.
The work will be centered at the company’s J.POD® facility in Redmond, Washington, which utilizes intensified continuous manufacturing to produce biologics at a fraction of the time and cost of traditional stainless-steel plants.
This "warm base" manufacturing capability allows the U.S. government to transition quickly from development to population-scale production if a public health emergency is declared.
This award follows a string of successful government collaborations for Evotec, including prior contracts with the Department of Defense for orthopoxvirus and plague treatments.